<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-133556" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV-2 Infection</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kapoor</surname>
            <given-names>Andrew K.</given-names>
          </name>
          <aff>Beth Israel Deaconess Medical Center, Harvard Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padival</surname>
            <given-names>Simi</given-names>
          </name>
          <aff>Beth Israel Deaconess Medical Center, Harvard Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Kapoor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Simi Padival declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-133556.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>HIV-2 is an enveloped retrovirus that causes infection in humans, similar to HIV-1. It is endemic to parts of West Africa, but globalization has led to worldwide spread. It is estimated that 1 to 2 million people live with HIV-2, and without treatment, infection invariably leads to significant morbidity and mortality. Given global interconnectedness and immigration from endemic regions, clinicians should become familiar with the differences between HIV-1 and HIV-2 infection and maintain a high index of suspicion for HIV-2 in persons from high-risk regions. This activity outlines the epidemiology, evaluation, diagnostic testing, and treatment options for HIV-2 infection. It further reviews the role interprofessional teams play in improving outcomes for patients with HIV-2.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the epidemiology&#x000a0;and transmission dynamics of HIV-2.</p></list-item><list-item><p>Identify the common pathophysiologic differences between HIV-1 and HIV-2.</p></list-item><list-item><p>Assess&#x000a0;the typical presentation of a patient with HIV-2 and its distinguishing features.</p></list-item><list-item><p>Determine&#x000a0;the main treatment strategies used by interprofessional team members and identify key treatment differences between HIV-1 and HIV-2.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133556&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133556">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-133556.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>HIV is an enveloped retrovirus that can be categorized into 2 distinct subtypes:&#x000a0;HIV type 1 (HIV-1) and&#x000a0;HIV type 2 (HIV-2). Although both viruses share similar transmission routes and can cause AIDS, there are important differences between them&#x000a0;regarding epidemiology, diagnosis, and management.<xref ref-type="bibr" rid="article-133556.r1">[1]</xref>&#x000a0;</p>
        <p>Although HIV-2 is less common globally, it is an important cause of disease in many regions. It predominates in West Africa, but globalization has led to a sizeable number of cases in other parts of Africa, Europe, India, and the United States.<xref ref-type="bibr" rid="article-133556.r2">[2]</xref>&#x000a0;It is currently estimated that about 1&#x000a0;to 2 million people are living with HIV-2 globally, although this is likely an underestimate.<xref ref-type="bibr" rid="article-133556.r3">[3]</xref></p>
        <p>The first cases of HIV-2 were detected in the United States in the late 1980s, and currently, about 1% of persons living with HIV in the US are estimated to have HIV-2.<xref ref-type="bibr" rid="article-133556.r4">[4]</xref>&#x000a0;Clinicians are generally less familiar with HIV-2, and disease-specific data are lacking. This has limited our contemporary understanding of prevalence, treatment, and monitoring in comparison to HIV-1.</p>
        <p>To date, the approach to HIV-2 has largely been extrapolated from studies in HIV-1, though notable differences exist. Its lower prevalence compared to HIV-1 has resulted in a paucity of drug trials or epidemiologic studies to address the current limitations in our understanding of HIV-2 management. However, given its global distribution, clinicians must become familiar with the differences between HIV-1 and HIV-2 while maintaining a high index of suspicion for HIV-2 in persons from endemic regions.</p>
      </sec>
      <sec id="article-133556.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HIV-2 is a viral zoonosis that infects humans similarly to HIV-1. Phylogenetic studies suggest it emerged from sooty mangabey monkeys infected with simian immunodeficiency virus (SIV) in Guinea-Bissau.<xref ref-type="bibr" rid="article-133556.r5">[5]</xref>&#x000a0;Molecular clock analyses indicate it likely crossed species from sooty mangabey monkeys into humans between the 1940s-1950s.<xref ref-type="bibr" rid="article-133556.r6">[6]</xref><xref ref-type="bibr" rid="article-133556.r7">[7]</xref>&#x000a0;However, the first case was not recognized until 1986 when a man from Guinea Bissau living in Portugal presented with severe immunodeficiency and negative HIV-1 testing.<xref ref-type="bibr" rid="article-133556.r8">[8]</xref>&#x000a0;Several years later, in 1989, the first case was identified in the United States when a woman from Cape Verde&#x000a0;presented with central nervous system toxoplasmosis, a common opportunistic infection seen in those with HIV-1.<xref ref-type="bibr" rid="article-133556.r9">[9]</xref></p>
        <p>The pandemic spread of HIV-2 was catalyzed by colonial wars being fought in Guinea and across West Africa during the 1960s&#x02013;1970s.<xref ref-type="bibr" rid="article-133556.r10">[10]</xref><xref ref-type="bibr" rid="article-133556.r11">[11]</xref>&#x000a0;This resulted in significant migration across West Africa and emigration to Europe. As conflicts continued, blood products were widely used to manage injuries, sexual networks emerged between military personnel and local communities, and widespread vaccination campaigns were enacted without modern sterilization techniques.<xref ref-type="bibr" rid="article-133556.r10">[10]</xref><xref ref-type="bibr" rid="article-133556.r12">[12]</xref>&#x000a0;</p>
        <p>The emergence of HIV-2 in Guinea Bissau, driven by these factors, led to rapid spread into neighboring countries and eventually to distant Portuguese colonies, including Cape Verde, Angola, Mozambique, India, and Brazil. Ultimately, this also resulted in significant levels of HIV-2 transmission in Portugal, which currently maintains the highest prevalence of HIV-2 infection in Europe.<xref ref-type="bibr" rid="article-133556.r13">[13]</xref></p>
      </sec>
      <sec id="article-133556.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Worldwide, most HIV infections are caused by HIV-1, and in 2018, an estimated 38 million people were infected globally.<xref ref-type="bibr" rid="article-133556.r14">[14]</xref>&#x000a0;HIV-2 infections make up the minority of cases, and it is estimated that about 1-2 million globally have HIV-2, though estimates have been difficult to ascertain.<xref ref-type="bibr" rid="article-133556.r15">[15]</xref>&#x000a0;The majority of cases are concentrated in West Africa, where HIV-2 is endemic. Prevalence rates are greater than 1% in Cape Verde, Guinea-Bissau, Senegal, The Gambia, Mali, Cote d&#x02019;Ivoire, Sierra Leone, and Nigeria.<xref ref-type="bibr" rid="article-133556.r3">[3]</xref><xref ref-type="bibr" rid="article-133556.r16">[16]</xref>&#x000a0;Although less common, HIV-2 infection has also been reported in several other regions, including Europe, South America, Asia, and the United States.<xref ref-type="bibr" rid="article-133556.r17">[17]</xref>&#x000a0;Between 2010&#x02013;2017, 198 cases of HIV-2 had been reported in the United States by the CDC.<xref ref-type="bibr" rid="article-133556.r4">[4]</xref><xref ref-type="bibr" rid="article-133556.r18">[18]</xref>&#x000a0;</p>
        <p>Of the new cases identified, 55% were diagnosed in the Northeast, with an additional 30% being diagnosed in the Southern United States.<xref ref-type="bibr" rid="article-133556.r4">[4]</xref>&#x000a0;The majority of US cases are acquired through heterosexual contact (61.1%), with a minority related to MSM (25.3%) or IVDU (11.6%).<xref ref-type="bibr" rid="article-133556.r4">[4]</xref>&#x000a0;In the United States, the overall prevalence of HIV-2 is thought to be approximately 0.5% to 1%, but historical limitations in HIV-2 testing suggest this is likely an underestimate.</p>
        <p>&#x000a0;Several studies have demonstrated that the demographics of HIV-2 are shifting.<xref ref-type="bibr" rid="article-133556.r12">[12]</xref>&#x000a0;The peak global incidence likely occurred sometime in the 1970-the 1980s, at which time Guinea Bissau had a remarkable point prevalence of 8% to 10%.<xref ref-type="bibr" rid="article-133556.r19">[19]</xref><xref ref-type="bibr" rid="article-133556.r20">[20]</xref>&#x000a0;HIV serostatus surveys in Guinea have supported this notion and found that prevalence among adults over 40 approaches 20%, while it remains low at 1% to 2% among younger adults.<xref ref-type="bibr" rid="article-133556.r10">[10]</xref>&#x000a0;However, prevalence rates across West African nations have steadily declined over the past several decades. In Guinea, prevalence had decreased from 8.3% in the 1990s to 4.7% by the mid-2000s, while concurrently, HIV-1 prevalence rose from 0.5% to 3.6% over the same period.<xref ref-type="bibr" rid="article-133556.r21">[21]</xref>&#x000a0;The reasons for this are unclear, but several studies have identified decreasing viral fitness, lower transmission efficiency, and competitive exclusion of HIV-1 as possible mechanisms.<xref ref-type="bibr" rid="article-133556.r22">[22]</xref><xref ref-type="bibr" rid="article-133556.r23">[23]</xref>&#x000a0; Phylogenetic and modeling studies have attributed up to 30% of the decline in HIV-2 prevalence to competitive exclusion, with the remaining 70% attributable to population-level sociobehavioral interventions.<xref ref-type="bibr" rid="article-133556.r24">[24]</xref><xref ref-type="bibr" rid="article-133556.r10">[10]</xref></p>
      </sec>
      <sec id="article-133556.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Compared to HIV-1, infection with HIV-2 is defined by 3&#x000a0;major differences:</p>
        <list list-type="order">
          <list-item>
            <p>A longer asymptomatic phase</p>
          </list-item>
          <list-item>
            <p>A slower rate of CD4 decline</p>
          </list-item>
          <list-item>
            <p>lower plasma viral loads.</p>
          </list-item>
        </list>
        <p>Given these significant advantages over HIV-1, it has historically been associated with overall lower mortality.<xref ref-type="bibr" rid="article-133556.r25">[25]</xref><xref ref-type="bibr" rid="article-133556.r26">[26]</xref>&#x000a0;However, more recent prospective cohort studies have shown that when left untreated, those with HIV-2 infection also progress to AIDS and death.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref>&#x000a0;Recent data has also demonstrated that although the asymptomatic phase of HIV-2 is longer, once CD4 counts drop below 200 cells/&#x000b5;L, the mortality rate seen in untreated HIV-2 infection is equivalent to those with untreated HIV-1.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref><xref ref-type="bibr" rid="article-133556.r2">[2]</xref></p>
        <p>The pathophysiologic differences noted above result in distinctly different natural histories when comparing HIV-1 and HIV-2. Those with HIV-2 have been shown to have half the rate of CD4 decline over time (0.4% vs. 0.9% per year) and, on average, have viral loads that are 28-fold lower after seroconversion.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref><xref ref-type="bibr" rid="article-133556.r28">[28]</xref><xref ref-type="bibr" rid="article-133556.r27">[27]</xref>&#x000a0;These factors contribute to a longer asymptomatic disease phase and result in longer AIDS-free survival. A study in commercial sex workers from Senegal highlighted this finding that 5-year survival among those with HIV-1 was half that of their HIV-2 infected counterparts.<xref ref-type="bibr" rid="article-133556.r29">[29]</xref>&#x000a0;</p>
        <p>Data from another HIV-2 cohort quantified median survival more granularly. It was noted that those with HIV-1 had a median survival of 8.2 years compared to 15.6 years among those with HIV-2.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref>&#x000a0;A significant difference in the time to AIDS was also seen, with a median of 6.2 years in those with HIV-1 compared to 14.3 years in those with HIV-2.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref><xref ref-type="bibr" rid="article-133556.r30">[30]</xref>&#x000a0;These studies done before the widespread availability of antiretroviral therapy (ART) demonstrate the divergent natural histories seen in patients with HIV-1 and HIV-2 before marked CD4 decline.</p>
        <p>Although the natural history may differ, the transmission of HIV-2 occurs by the same routes as HIV-1, including perinatal, sexual contact, and bloodborne exposure. During the mechanisms of transmission overlap, HIV-2 is a markedly less efficient virus and, thus, significantly less infectious. Globally, this has resulted in disproportionately fewer cases of HIV-2 and a more limited spread in comparison to HIV-1. The comparatively lower efficiency of HIV-2 has been well illustrated in studies examining mother-to-child transmission from the pre-antiretroviral era. Remarkably, perinatal transmission among HIV-2 positive mothers has been notably low at 1% to 2%, whereas in mothers with HIV-1, transmission ranges from 15% to 30%.<xref ref-type="bibr" rid="article-133556.r31">[31]</xref><xref ref-type="bibr" rid="article-133556.r32">[32]</xref>&#x000a0;Perinatal cohort studies from West Africa have demonstrated this is likely driven by factors specific to HIV-2, including lower pretreatment viral loads among peripartum women and decreased viral shedding in the female genital tract during delivery.<xref ref-type="bibr" rid="article-133556.r33">[33]</xref>&#x000a0;&#x000a0;</p>
        <p>Interestingly, dual infection with both HIV-1 and HIV-2 can occur in regions where both viruses circulate widely. It has most commonly been reported in West Africa, where seroprevalence studies estimate dual infection in up to 5% to 10% of those infected.<xref ref-type="bibr" rid="article-133556.r30">[30]</xref>&#x000a0;Initially, several small cohorts and experimental studies in non-human primates suggested primary infection with HIV-2 may reduce the likelihood of subsequent HIV-1 acquisition and slow disease progression in those who were co-infected.<xref ref-type="bibr" rid="article-133556.r29">[29]</xref><xref ref-type="bibr" rid="article-133556.r34">[34]</xref><xref ref-type="bibr" rid="article-133556.r29">[29]</xref>&#x000a0;More recent data suggest that primary HIV-2 infection and the resulting HIV antibodies have no protective effect on HIV-1 acquisition. Long-term data has also illustrated that dually infected patients follow the expected disease trajectory of those with HIV-1 mono-infection.<xref ref-type="bibr" rid="article-133556.r35">[35]</xref></p>
      </sec>
      <sec id="article-133556.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>All patients diagnosed with HIV-2 should have a complete medical history, physical examination, and laboratory evaluation&#x000a0;similar to that of a patient infected with HIV-1. The goal of an initial evaluation is to confirm the diagnosis of HIV-2, screen for and identify any opportunistic infections, provide patients with education and support, and discuss the benefits of antiretroviral therapy. Because of the natural history of undiagnosed HIV-2, clinicians should be aware that patients may present at older ages, represent a different demographic, or have non-traditional risk factors upon diagnosis. Thus, a low threshold should be maintained in sending HIV-2 testing, particularly in patients with epidemiologic risk.</p>
        <p>Those with HIV-2 often present with similar clinical symptoms as those with HIV-1, including developing an acute retroviral syndrome or opportunistic infection. All opportunistic infections have been seen in patients with HIV-2, including oral candidiasis, <italic toggle="yes">Pneumocystis</italic>&#x000a0;pneumonia, cytomegalovirus, Kaposi sarcoma, tuberculosis, disseminated mycobacterial infection, toxoplasmosis, and progressive multifocal leukoencephalopathy, among others.<xref ref-type="bibr" rid="article-133556.r27">[27]</xref><xref ref-type="bibr" rid="article-133556.r36">[36]</xref><xref ref-type="bibr" rid="article-133556.r37">[37]</xref><xref ref-type="bibr" rid="article-133556.r38">[38]</xref>&#x000a0;</p>
        <p>Evaluation for co-infection and concurrent opportunistic infection should be methodical and follow the guidelines outlined for HIV-1 infection.<xref ref-type="bibr" rid="article-133556.r39">[39]</xref>&#x000a0;Importantly, dual infection with HIV-1 should be ruled out early as part of initial laboratory testing.</p>
        <p>In a study of HIV-2 from The Gambia, the most common AIDS-defining feature at presentation was generalized wasting and pulmonary TB, although these findings may not be globally generalizable. Few studies have compared the frequency of OIs in patients with HIV-1 to those with HIV-2, but some evidence suggests that encephalitis may occur more frequently in those with HIV-2. It remains unclear if this may be related to longer survival times or differences in neurotropism between HIV-1 and HIV-2.<xref ref-type="bibr" rid="article-133556.r38">[38]</xref><xref ref-type="bibr" rid="article-133556.r1">[1]</xref>&#x000a0;In addition, HIV-associated nephropathy (HIVAN), which occurs in about 10% of patients with HIV-1, has been rarely described among patients with HIV-2.<xref ref-type="bibr" rid="article-133556.r40">[40]</xref><xref ref-type="bibr" rid="article-133556.r41">[41]</xref></p>
      </sec>
      <sec id="article-133556.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Historically, the diagnosis of HIV-2 has been challenged by several issues, including HIV antibody differentiation and the detection of plasma HIV-2 RNA levels. Before the widespread availability of the 4th generation HIV-1/2 antigen-antibody tests, clinicians had to rely on clinical suspicion to determine when HIV-2-specific testing was appropriate. Such scenarios included declining CD4 counts in an HIV-1 patient on appropriate therapy, untreated HIV-positive patients with an undetectable viral load, or those with opportunistic infection from West Africa. Previous immunoassays effectively detected HIV-1 and HIV-2 antibodies but did not differentiate between them. Confirmatory western blots were used, but cross-reactivity between HIV-1 and HIV-2 antibodies often resulted in indeterminate results or misdiagnosis as HIV-1.</p>
        <p>Many of these limitations have been mitigated by the widespread use of the 4th generation HIV-1/2 antigen-antibody testing, which includes a differentiation assay. Consequently, in 2014, the Centers for Disease Control (CDC) revised its HIV testing algorithm to improve the diagnosis of HIV-2 by including the differentiation assay results.<xref ref-type="bibr" rid="article-133556.r42">[42]</xref>&#x000a0;</p>
        <p>The testing algorithm was revised in 2018 and should be used by all clinicians when interpreting diagnostic testing results for HIV.<xref ref-type="bibr" rid="article-133556.r43">[43]</xref> Commercially available HIV-2 viral load testing remains challenging, and currently, there are only&#x000a0;2 labs that routinely carry out this testing in the United States. Further complicating HIV-2 plasma viral load testing is the appreciation that up to 40% of patients with HIV-2 have an undetectable viral load without ART.<xref ref-type="bibr" rid="article-133556.r44">[44]</xref>&#x000a0;Thus, viral load testing should be considered unreliable. Though it can be useful to confirm a diagnosis of HIV-2 and monitor treatment in some cases, it cannot rule out infection. Resistance testing is also unavailable, and currently, there are no validated HIV-2 genotypic or phenotypic resistance assays approved for clinical use in the United States.</p>
      </sec>
      <sec id="article-133556.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goals of ART in HIV-2 are similar to those for HIV-1&#x02013;prevention of transmission, immune restoration, durable viral suppression, and a reduction in morbidity and mortality.<xref ref-type="bibr" rid="article-133556.r45">[45]</xref> However, there are very few trials in HIV-2 to specifically address when ART should be started, what agents may work best, or which regimens should be used in the setting of virologic failure.<xref ref-type="bibr" rid="article-133556.r46">[46]</xref> Most treatment data used to guide HIV-2 management has been extrapolated from the wealth of studies&#x000a0;performed on HIV-1 patients. Despite the lack of clinical evidence, it is clear that several combination therapies used in HIV-1 are also very effective in treating those with HIV-2.<xref ref-type="bibr" rid="article-133556.r47">[47]</xref><xref ref-type="bibr" rid="article-133556.r48">[48]</xref><xref ref-type="bibr" rid="article-133556.r49">[49]</xref></p>
        <p>Currently, it is recommended that all patients diagnosed with HIV-2 be started on ART as soon as possible after diagnosis.<xref ref-type="bibr" rid="article-133556.r50">[50]</xref>&#x000a0;The first line of recommended treatments includes either a combination of&#x000a0;2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI) or&#x000a0;2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a boosted protease inhibitor (PI) with either darunavir or lopinavir.<xref ref-type="bibr" rid="article-133556.r51">[51]</xref>&#x000a0;It is important to note that HIV-2 has intrinsic drug resistance to all non-nucleoside reverse transcriptase inhibitors (NNRTI), rendering them ineffective.<xref ref-type="bibr" rid="article-133556.r52">[52]</xref> In addition, most PIs are ineffective except for darunavir, lopinavir, and saquinavir.<xref ref-type="bibr" rid="article-133556.r53">[53]</xref></p>
        <p>The fusion inhibitor enfuvirtide also has no HIV-2 activity and should not be used. These drug resistance patterns result from natural polymorphisms in HIV-2 that result in ineffective or less effective binding to comparable drug target sites in HIV-1.<xref ref-type="bibr" rid="article-133556.r54">[54]</xref> This occurs primarily through conformational variants in the wild-type HIV-2 reverse transcriptase and protease enzymes.<xref ref-type="bibr" rid="article-133556.r55">[55]</xref></p>
        <p>The initial monitoring of patients with HIV-2 should follow the same recommended guidelines set out for HIV-1 patients, except for baseline resistance testing. To determine treatment progress, clinicians can follow CD4 counts and HIV-2 viral loads if they are available. However, treatment failure should be suspected in patients with undetectable baseline viral loads if disease progression or continued CD4 decline occurs.</p>
      </sec>
      <sec id="article-133556.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>HIV-2 should be considered in those with epidemiologic risk factors or an opportunistic infection. As such, the differential is broad and includes a range of diseases caused by opportunistic and sexually transmitted pathogens.</p>
        <list list-type="bullet">
          <list-item>
            <p>HIV-1 infection</p>
          </list-item>
          <list-item>
            <p>Dual infection with HIV-1 and HIV-2</p>
          </list-item>
          <list-item>
            <p>Hepatitis B</p>
          </list-item>
          <list-item>
            <p>Hepatitis C</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Pneumocystis jiroveci&#x000a0;</italic>pneumonia</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Toxoplasma gondii&#x000a0;</italic>encephalitis</p>
          </list-item>
          <list-item>
            <p>Cryptosporidiosis</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">Mycobacterium tuberculosis</italic>
</p>
          </list-item>
          <list-item>
            <p>Nontuberculous mycobacterial Infection (NTM)</p>
          </list-item>
          <list-item>
            <p>Bartonellosis</p>
          </list-item>
          <list-item>
            <p>Syphilis</p>
          </list-item>
          <list-item>
            <p>Mucocutaneous candidiasis</p>
          </list-item>
          <list-item>
            <p>Cryptococcosis</p>
          </list-item>
          <list-item>
            <p>Histoplasmosis</p>
          </list-item>
          <list-item>
            <p>Coccidioidomycosis</p>
          </list-item>
          <list-item>
            <p>Aspergillosis</p>
          </list-item>
          <list-item>
            <p>Cytomegalovirus</p>
          </list-item>
          <list-item>
            <p>Herpes simplex virus</p>
          </list-item>
          <list-item>
            <p>Varicella zoster virus</p>
          </list-item>
          <list-item>
            <p>Human herpesvirus-8/Kaposi sarcoma</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal leukoencephalopathy (PML)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133556.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>There is an overall paucity of data on the prognosis and outcomes of those living with HIV-2, and existing studies have been small. However, HIV-2 cohorts have consistently shown that in&#x000a0;patients with CD4 cell counts greater than 500 cells/&#x000b5;L, survival is improved compared to age-matched controls with HIV-1.<xref ref-type="bibr" rid="article-133556.r30">[30]</xref><xref ref-type="bibr" rid="article-133556.r35">[35]</xref>&#x000a0;</p>
        <p>Further studies have demonstrated that in those with HIV-2 and advanced disease, mortality rates are similar to patients with HIV-1 when adjusted for CD4 count, age, and demographic factors.<xref ref-type="bibr" rid="article-133556.r56">[56]</xref>&#x000a0;Currently, there is limited data on whether long-term mortality rates or non-AIDS-related comorbidities are similar when comparing HIV-2 and HIV-1 patients on antiretroviral therapy.<xref ref-type="bibr" rid="article-133556.r57">[57]</xref></p>
      </sec>
      <sec id="article-133556.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The complications from chronic infection with HIV-2 are similar to those in patients with HIV-1. Once patients with HIV-2 have developed advanced immunosuppression with CD4 cell counts less than 200 cells/&#x000b5;L, they are at risk of developing the same types of opportunistic infections seen in HIV-1.<xref ref-type="bibr" rid="article-133556.r2">[2]</xref> As in those with HIV-1, the risk for these infectious complications can be minimized by initiating ART and the resultant immune reconstitution. Although there is no data specifically from HIV-2 patient cohorts, the same primary prophylaxis is recommended for those with CD4 counts below 200 cells/&#x000b5;L to prevent opportunistic infection with common pathogens such as <italic toggle="yes">Pneumocystis jiroveci</italic> and <italic toggle="yes">Toxoplasma gondii.</italic><xref ref-type="bibr" rid="article-133556.r38">[38]</xref></p>
      </sec>
      <sec id="article-133556.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Sexual contact is the primary mode of transmission for HIV-2, and patients at risk should be counseled about safe sexual practices and encouraged to get routine testing. Counseling should be culturally competent, sensitive to issues of sexual identity, and tailored to each patient's risk. If other risk factors are present, including the use of intravenous drugs, specific harm reduction strategies or interventions should be offered to mitigate transmission from contaminated equipment.</p>
        <p>Pre-exposure prophylaxis (PrEP) should be offered to patients at substantial risk of acquiring HIV infection. Although there are no data specifically addressing PrEP in preventing HIV-2, the antiretrovirals used for PrEP are active against both HIV-1 and HIV-2, and similarly, high levels of efficacy would be expected.<xref ref-type="bibr" rid="article-133556.r58">[58]</xref> Currently, less is known about the potential efficacy of long-acting injectable PrEP in the prevention of HIV-2, though recent in vitro studies have shown cabotegravir to have efficacy against HIV-2.<xref ref-type="bibr" rid="article-133556.r59">[59]</xref></p>
      </sec>
      <sec id="article-133556.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach involving clinicians, mid-level practitioners, specialists, nurses, and pharmacists is essential in managing HIV-2 infection, given it can be complex and lifelong. The clinical care team should involve an infectious disease specialist with expertise in HIV care, a social worker, a pharmacist, and other specialist care if needed. Central to the care team is the patient, and focus should be paid to ensuring the HIV care team provides strong, unified communication, clear disease understanding, and a supportive environment. Providing an interprofessional care team has been shown among HIV-1 patients to improve important outcomes such as virologic suppression and patient retention.<xref ref-type="bibr" rid="article-133556.r60">[60]</xref><xref ref-type="bibr" rid="article-133556.r61">[61]</xref>&#x000a0;</p>
        <p>Similar outcomes could be expected for those living with HIV-2, given the significant overlap in clinical services and support required to manage patients successfully. The role of long-acting injectable agents and the uptake of telemedicine may present both new opportunities and challenges for multidisciplinary teams caring for those with HIV. However, as HIV clinical care continues to evolve, multidisciplinary teams must continue working synergistically to maximize patient engagement, retention, and virologic suppression.</p>
      </sec>
      <sec id="article-133556.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133556&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133556">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-2-infection/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=133556">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/133556/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=133556">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-133556.s15">
        <title>References</title>
        <ref id="article-133556.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nyamweya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hegedus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Macallan</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.</article-title>
            <source>Rev Med Virol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-40</page-range>
            <pub-id pub-id-type="pmid">23444290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell-Yesufu</surname>
                <given-names>OT</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Update on human immunodeficiency virus (HIV)-2 infection.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Mar</month>
            <day>15</day>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>780</fpage>
            <page-range>780-7</page-range>
            <pub-id pub-id-type="pmid">21367732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Raugi</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2.</article-title>
            <source>Lancet HIV</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>e390</fpage>
            <page-range>e390-e399</page-range>
            <pub-id pub-id-type="pmid">30052509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peruski</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Wesolowski</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Granade</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Switzer</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2020</year>
            <month>Jan</month>
            <day>24</day>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>63</fpage>
            <page-range>63-66</page-range>
            <pub-id pub-id-type="pmid">31971928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Visseaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Charpentier</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hiv-2 molecular epidemiology.</article-title>
            <source>Infect Genet Evol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>46</volume>
            <fpage>233</fpage>
            <page-range>233-240</page-range>
            <pub-id pub-id-type="pmid">27530215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sow</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ndoye</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coll-Seck</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Curlin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Critchlow</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kiviat</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>575</fpage>
            <page-range>575-84</page-range>
            <pub-id pub-id-type="pmid">12908935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pybus</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saksena</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Salemi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vandamme</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Tracing the origin and history of the HIV-2 epidemic.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2003</year>
            <month>May</month>
            <day>27</day>
            <volume>100</volume>
            <issue>11</issue>
            <fpage>6588</fpage>
            <page-range>6588-92</page-range>
            <pub-id pub-id-type="pmid">12743376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clavel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>HIV-2, the West African AIDS virus.</article-title>
            <source>AIDS</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-40</page-range>
            <pub-id pub-id-type="pmid">3126752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kloser</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Mangia</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lombardo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Michaels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Denny</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Sharer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sathe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Schable</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>HIV-2-associated AIDS in the United States. The first case.</article-title>
            <source>Arch Intern Med</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>149</volume>
            <issue>8</issue>
            <fpage>1875</fpage>
            <page-range>1875-7</page-range>
            <pub-id pub-id-type="pmid">2764658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Silva</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>van Tienen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Onyango</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jabang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Loeff</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cotten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic.</article-title>
            <source>AIDS</source>
            <year>2013</year>
            <month>Jan</month>
            <day>02</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-34</page-range>
            <pub-id pub-id-type="pmid">23032414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendoza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lozano</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cabezas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions.</article-title>
            <source>AIDS Rev</source>
            <year>2020</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-56</page-range>
            <pub-id pub-id-type="pmid">32167506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.</article-title>
            <source>AIDS</source>
            <year>2013</year>
            <month>Jan</month>
            <day>02</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-7</page-range>
            <pub-id pub-id-type="pmid">23221427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvalho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Valadas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fran&#x000e7;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aleixo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mendez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarmento</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doroana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Branco</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aguas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarmento E Castro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Population mobility and the changing epidemics of HIV-2 in Portugal.</article-title>
            <source>HIV Med</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-25</page-range>
            <pub-id pub-id-type="pmid">22136745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Deltoro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis.</article-title>
            <source>AIDS Rev</source>
            <year>2019</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-64</page-range>
            <pub-id pub-id-type="pmid">31332395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Silva</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Cotten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>HIV-2: the forgotten AIDS virus.</article-title>
            <source>Trends Microbiol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>588</fpage>
            <page-range>588-95</page-range>
            <pub-id pub-id-type="pmid">18964021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Cock</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Adjorlolo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ekpini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sibailly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kouadio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brattegaard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vetter</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Doorly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gayle</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.</article-title>
            <source>JAMA</source>
            <year>1993</year>
            <month>Nov</month>
            <day>03</day>
            <volume>270</volume>
            <issue>17</issue>
            <fpage>2083</fpage>
            <page-range>2083-6</page-range>
            <pub-id pub-id-type="pmid">8147962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Remy</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[HIV-2 infection in the world. A geographical perspective].</article-title>
            <source>Sante</source>
            <year>1998</year>
            <season>Nov-Dec</season>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>440</fpage>
            <page-range>440-6</page-range>
            <pub-id pub-id-type="pmid">10064918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>HIV-2 Infection Surveillance--United States, 1987-2009.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2011</year>
            <month>Jul</month>
            <day>29</day>
            <volume>60</volume>
            <issue>29</issue>
            <fpage>985</fpage>
            <page-range>985-8</page-range>
            <pub-id pub-id-type="pmid">21796096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poulsen</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kvinesdal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000f8;lbak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frederiksen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauritzen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa.</article-title>
            <source>Lancet</source>
            <year>1989</year>
            <month>Apr</month>
            <day>15</day>
            <volume>1</volume>
            <issue>8642</issue>
            <fpage>827</fpage>
            <page-range>827-31</page-range>
            <pub-id pub-id-type="pmid">2564911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paulo Da Silva</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of HIV infection in a rural area of Guinea-Bissau.</article-title>
            <source>AIDS</source>
            <year>1993</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>1119</fpage>
            <page-range>1119-22</page-range>
            <pub-id pub-id-type="pmid">8397950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tienen</surname>
                <given-names>Cv</given-names>
              </name>
              <name>
                <surname>van der Loeff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sarge-Njie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Leligdowicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>640</fpage>
            <page-range>640-7</page-range>
            <pub-id pub-id-type="pmid">19841588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sandstr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Melbye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Naucl&#x000e9;r</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau.</article-title>
            <source>AIDS</source>
            <year>1998</year>
            <month>Sep</month>
            <day>10</day>
            <volume>12</volume>
            <issue>13</issue>
            <fpage>1707</fpage>
            <page-range>1707-14</page-range>
            <pub-id pub-id-type="pmid">9764792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmgren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?</article-title>
            <source>AIDS</source>
            <year>2008</year>
            <month>Jun</month>
            <day>19</day>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1195</fpage>
            <page-range>1195-202</page-range>
            <pub-id pub-id-type="pmid">18525265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Van Der Loeff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Aaby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau.</article-title>
            <source>Epidemiol Infect</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>551</fpage>
            <page-range>551-61</page-range>
            <pub-id pub-id-type="pmid">17559692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alabi</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jaffar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ariyoshi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schim van der Loeff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Awasana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Corrah</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sabally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarge-Njie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cham-Jallow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients.</article-title>
            <source>AIDS</source>
            <year>2003</year>
            <month>Jul</month>
            <day>04</day>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1513</fpage>
            <page-range>1513-20</page-range>
            <pub-id pub-id-type="pmid">12824789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ariyoshi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaffar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corrah</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tedder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection.</article-title>
            <source>J Hum Virol</source>
            <year>1998</year>
            <season>Nov-Dec</season>
            <volume>1</volume>
            <issue>7</issue>
            <fpage>457</fpage>
            <page-range>457-68</page-range>
            <pub-id pub-id-type="pmid">10195267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esbj&#x000f6;rnsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kvist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feny&#x000f6;</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Isberg</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Biague</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lindman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palm</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medstrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Norrgren</surname>
                <given-names>H</given-names>
              </name>
              <collab>Sweden and Guinea-Bissau Cohort Research Group</collab>
            </person-group>
            <article-title>Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.</article-title>
            <source>Lancet HIV</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <pub-id pub-id-type="pmid">30392769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Norrgren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Biague</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bamba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christopherson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Biberfeld</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.</article-title>
            <source>Arch Intern Med</source>
            <year>2000</year>
            <month>Nov</month>
            <day>27</day>
            <volume>160</volume>
            <issue>21</issue>
            <fpage>3286</fpage>
            <page-range>3286-93</page-range>
            <pub-id pub-id-type="pmid">11088091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marlink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kanki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thior</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Siby</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Traore</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Dia</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gueye</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Reduced rate of disease development after HIV-2 infection as compared to HIV-1.</article-title>
            <source>Science</source>
            <year>1994</year>
            <month>Sep</month>
            <day>09</day>
            <volume>265</volume>
            <issue>5178</issue>
            <fpage>1587</fpage>
            <page-range>1587-90</page-range>
            <pub-id pub-id-type="pmid">7915856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schim van der Loeff</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Jaffar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aveika</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sabally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corrah</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bayang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariyoshi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia.</article-title>
            <source>AIDS</source>
            <year>2002</year>
            <month>Sep</month>
            <day>06</day>
            <volume>16</volume>
            <issue>13</issue>
            <fpage>1775</fpage>
            <page-range>1775-83</page-range>
            <pub-id pub-id-type="pmid">12218389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adjorlolo-Johnson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Cock</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ekpini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vetter</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sibailly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brattegaard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yavo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doorly</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kestens</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast.</article-title>
            <source>JAMA</source>
            <year>1994</year>
            <month>Aug</month>
            <day>10</day>
            <volume>272</volume>
            <issue>6</issue>
            <fpage>462</fpage>
            <page-range>462-6</page-range>
            <pub-id pub-id-type="pmid">8040982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jasseron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hamrene</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rouzioux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Warszawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mandelbro</surname>
                <given-names>L</given-names>
              </name>
              <collab>ANRS French Perinatal Cohort EPF-CO1</collab>
            </person-group>
            <article-title>Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Oct</month>
            <day>01</day>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>833</fpage>
            <page-range>833-43</page-range>
            <pub-id pub-id-type="pmid">20804413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghys</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Fransen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diallo</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Etti&#x000e8;gne-Traor&#x000e9;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Coulibaly</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Yebou&#x000e9;</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kalish</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Maurice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Laga</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, C&#x000f4;te d'Ivoire.</article-title>
            <source>AIDS</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>F85</fpage>
            <page-range>F85-93</page-range>
            <pub-id pub-id-type="pmid">9342059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esbj&#x000f6;rnsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kvist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isberg</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Nowroozalizadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biague</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feny&#x000f6;</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Norrgren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Medstrand</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jul</month>
            <day>19</day>
            <volume>367</volume>
            <issue>3</issue>
            <fpage>224</fpage>
            <page-range>224-32</page-range>
            <pub-id pub-id-type="pmid">22808957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prince</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Matser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Tienen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Schim van der Loeff</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis.</article-title>
            <source>AIDS</source>
            <year>2014</year>
            <month>Feb</month>
            <day>20</day>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-58</page-range>
            <pub-id pub-id-type="pmid">23921613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jespersen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katzenstein</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000e9;</surname>
                <given-names>Dda S</given-names>
              </name>
              <name>
                <surname>Correira</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Hviid</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Laursen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wejse</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and opportunistic infections in HIV-1, HIV-2 and HIV-1/2 dual seropositive patients in Guinea-Bissau.</article-title>
            <source>Infect Dis (Lond)</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>604</fpage>
            <page-range>604-11</page-range>
            <pub-id pub-id-type="pmid">27163507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Sande</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schim van der Loeff</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aveika</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Togun</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Sabally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeffries</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adegbola</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sarge-Njie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corrah</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McConkey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2.</article-title>
            <source>AIDS</source>
            <year>2004</year>
            <month>Sep</month>
            <day>24</day>
            <volume>18</volume>
            <issue>14</issue>
            <fpage>1933</fpage>
            <page-range>1933-41</page-range>
            <pub-id pub-id-type="pmid">15353979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hounnou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beaumel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Djomand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>N'Gbichi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yeboue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hond&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diomande</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The mortality and pathology of HIV infection in a west African city.</article-title>
            <source>AIDS</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1569</fpage>
            <page-range>1569-79</page-range>
            <pub-id pub-id-type="pmid">7904450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Churchill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Angus</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boffito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fidler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orkin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palfreeman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trevelion</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.</article-title>
            <source>HIV Med</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>17 Suppl 4</volume>
            <fpage>s2</fpage>
            <page-range>s2-s104</page-range>
            <pub-id pub-id-type="pmid">27568911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haragsim</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Laszik</surname>
                <given-names>ZG</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated nephropathy.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-13</page-range>
            <pub-id pub-id-type="pmid">16815235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Izzedine</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brocheriou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ghosn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lassal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>HIV-2 infection and HIV-associated nephropathy.</article-title>
            <source>AIDS</source>
            <year>2006</year>
            <month>Apr</month>
            <day>04</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>949</fpage>
            <page-range>949-50</page-range>
            <pub-id pub-id-type="pmid">16549986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>National HIV Testing Day and new testing recommendations.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2014</year>
            <month>Jun</month>
            <day>27</day>
            <volume>63</volume>
            <issue>25</issue>
            <fpage>537</fpage>
            <pub-id pub-id-type="pmid">25095328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Raugi</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Seilie</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bogusz</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seydi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Coombs</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.</article-title>
            <source>J Clin Virol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>86</volume>
            <fpage>56</fpage>
            <page-range>56-61</page-range>
            <pub-id pub-id-type="pmid">27951466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sarr</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gu&#x000e8;ye-Ndiaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mboup</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Essex</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kanki</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.</article-title>
            <source>J Infect Dis</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>180</volume>
            <issue>4</issue>
            <fpage>1116</fpage>
            <page-range>1116-21</page-range>
            <pub-id pub-id-type="pmid">10479138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Progress in the HIV epidemic: Identifying goals and measuring success.</article-title>
            <source>PLoS Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>e1002729</fpage>
            <pub-id pub-id-type="pmid">30657770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Eholi&#x000e9;</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Nkengasong</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Jallow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rowland-Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Sow</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.</article-title>
            <source>AIDS</source>
            <year>2008</year>
            <month>Oct</month>
            <day>18</day>
            <volume>22</volume>
            <issue>16</issue>
            <fpage>2069</fpage>
            <page-range>2069-72; discussion 2073-4</page-range>
            <pub-id pub-id-type="pmid">18832869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gallien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Besseghir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sellier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Charpentier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tubiana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peytavin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ponscarme</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brun-Vezinet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chene</surname>
                <given-names>G</given-names>
              </name>
              <collab>France REcherche Nord&#x00026;Sud Sida-Hiv H&#x000e9;patites (ANRS) 159 HIV-2 Trial Study Group</collab>
            </person-group>
            <article-title>First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <day>28</day>
            <volume>67</volume>
            <issue>8</issue>
            <fpage>1161</fpage>
            <page-range>1161-1167</page-range>
            <pub-id pub-id-type="pmid">29590335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raugi</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hawes</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sow</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Seydi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <collab>University of Washington&#x02013;Dakar HIV-2 Study Group</collab>
            </person-group>
            <article-title>A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Oct</month>
            <day>30</day>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1588</fpage>
            <page-range>1588-1594</page-range>
            <pub-id pub-id-type="pmid">29672676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;nard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Campa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peytavin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lascoux-Combes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Autran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brun-V&#x000e9;zinet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ch&#x000ea;ne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <collab>ANRS CO5 HIV-2 Cohort Study Group</collab>
            </person-group>
            <article-title>Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.</article-title>
            <source>AIDS</source>
            <year>2009</year>
            <month>Jun</month>
            <day>01</day>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1171</fpage>
            <page-range>1171-3</page-range>
            <pub-id pub-id-type="pmid">19349850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>INSIGHT START Study Group</collab>
              <name>
                <surname>Lundgren</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Babiker</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Gordin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grund</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avihingsanon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Llibre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Munderi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schechter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klingman</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>27</day>
            <volume>373</volume>
            <issue>9</issue>
            <fpage>795</fpage>
            <page-range>795-807</page-range>
            <pub-id pub-id-type="pmid">26192873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;nthard</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gallant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Volberding</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>316</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-210</page-range>
            <pub-id pub-id-type="pmid">27404187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vail</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Merrick</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Radix</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <source>Diagnosis and Management of HIV-2 in Adults [Internet]</source>
            <publisher-name>Johns Hopkins University</publisher-name>
            <publisher-loc>Baltimore (MD)</publisher-loc>
            <year>2023</year>
            <month>06</month>
            <pub-id pub-id-type="pmid">32573998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charpentier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Visseaux</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>B&#x000e9;nard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peytavin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Damond</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ch&#x000ea;ne</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brun-V&#x000e9;zinet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Descamps</surname>
                <given-names>D</given-names>
              </name>
              <collab>ANRS CO5 HIV-2 Cohort</collab>
            </person-group>
            <article-title>Transmitted drug resistance in French HIV-2-infected patients.</article-title>
            <source>AIDS</source>
            <year>2013</year>
            <month>Jun</month>
            <day>19</day>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1671</fpage>
            <page-range>1671-4</page-range>
            <pub-id pub-id-type="pmid">23595155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Raugi</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <collab>University of Washington-Dakar HIV-2 Study Group</collab>
            </person-group>
            <article-title>HIV Drug Resistance.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>378</volume>
            <issue>9</issue>
            <fpage>874</fpage>
            <page-range>874-5</page-range>
            <pub-id pub-id-type="pmid">29504389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laville</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fartek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cerisier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Flatters</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petitjean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regad</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.</article-title>
            <source>BMC Mol Cell Biol</source>
            <year>2020</year>
            <month>Jun</month>
            <day>23</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">32576133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez-Steele</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Awasana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Corrah</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sabally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van der Sande</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Togun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sarge-Njie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McConkey</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schim van der Loeff</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.</article-title>
            <source>AIDS</source>
            <year>2007</year>
            <month>Jan</month>
            <day>30</day>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-24</page-range>
            <pub-id pub-id-type="pmid">17255738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tchounga</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ekouevi</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Balestre</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dabis</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mortality and survival patterns of people living with HIV-2.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>537</fpage>
            <page-range>537-544</page-range>
            <pub-id pub-id-type="pmid">27254747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witvrouw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pannecouque</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Switzer</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Folks</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>De Clercq</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heneine</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.</article-title>
            <source>Antivir Ther</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-65</page-range>
            <pub-id pub-id-type="pmid">15040537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Zavala</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Raugi</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seydi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>GS</given-names>
              </name>
              <collab>University of Washington-Dakar HIV-2 Study Group</collab>
            </person-group>
            <article-title><italic>In Vitro</italic> Antiviral Activity of Cabotegravir against HIV-2.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">30012774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ojikutu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kunches</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perlmutter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fant</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hirschhorn</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Interdisciplinary HIV care in a changing healthcare environment in the USA.</article-title>
            <source>AIDS Care</source>
            <year>2014</year>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>731</fpage>
            <page-range>731-5</page-range>
            <pub-id pub-id-type="pmid">24191727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133556.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doshi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Milberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Malitz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matosky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trent-Adams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parham Hopson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cheever</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV/AIDS Program, 2011.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <day>01</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-25</page-range>
            <pub-id pub-id-type="pmid">25225233</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
